Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-04-12 00:00:00 ET · period of report 2022-04-08 · accession 0000899243-22-014548 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-04-12 | 2022-04-08 | VRTX | MCGLYNN MARGARET G | Dir | S - Sale+OE | $280.22 | -5,000 | 1,099 | -82% | -$1.40M |
| D | 2022-04-12 | 2022-04-08 | VRTX | MCGLYNN MARGARET G | Dir | M - OptEx | $127.54 | +5,000 | 6,099 | +455% | +$637.7K |
| D | 2022-04-12 | 2022-04-08 | VRTX | MCGLYNN MARGARET G | Dir | M - OptEx | $0.00 | -5,000 | 5,000 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-08 | S | D | 4,900 | $280.19 | 1,199 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $280.19 (range $280.00 to $280.95). (F2) Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2022-04-08 | S | D | 100 | $281.49 | 1,099 | D | — | — | |
| 3 | Common | Common Stock | 2022-04-08 | M | A | 5,000 | $127.54 | 6,099 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-04-08 | M | D | 5,000 | $0.00 | 5,000 | D | $127.54 · — to 2025-05-31 | 5,000 Common Stock | (F4) Fully vested. |